Cargando…

Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents

Circulating biomarkers have emerged as valuable surrogates for evaluating disease states in solid malignancies. Their relative ease of access and rapid turnover has bolstered clinical applications in monitoring treatment efficacy and cancer progression. In this review, the roles of various circulati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janse van Rensburg, Helena J, Spiliopoulou, Pavlina, Siu, Lillian L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Cancer Diagnostics and Molecular Pathology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074993/ https://www.ncbi.nlm.nih.gov/pubmed/35285488 http://dx.doi.org/10.1093/oncolo/oyac047

Ejemplares similares

Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms
por: Franses, Joseph W., et al.
Publicado: (2017)

The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs
por: Mohamed, Luqmaan, et al.
Publicado: (2022)

The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms
por: Liu, Man, et al.
Publicado: (2023)

Circulating cell-free miRNAs as biomarker for triple-negative breast cancer
por: Shin, V Y, et al.
Publicado: (2015)

Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator
por: Stenzinger, Albrecht, et al.
Publicado: (2023)

Validation of a Circulating Tumor DNA‐Based Next‐Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing
por: Al Zoughbi, Wael, et al.
Publicado: (2021)

Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers
por: Girard, Nicolas, et al.
Publicado: (2022)

One‐Step Polymerase Chain Reaction‐Free Nanowire‐Based Plasma Cell‐Free DNA Assay to Detect EML4‐ALK Fusion and to Monitor Resistance in Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2021)

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors
por: Takeda, Masayuki, et al.
Publicado: (2021)

Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901)
por: Peng, Wenying, et al.
Publicado: (2022)

Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions
por: Jardim, Denis L., et al.
Publicado: (2020)

Monitoring gastric cancer progression with circulating tumour DNA
por: Hamakawa, T, et al.
Publicado: (2015)

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes
por: Shapira, I, et al.
Publicado: (2014)

Combined Expression of Plasma Thrombospondin‐2 and CA19‐9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach
por: Le Large, Tessa Y.S., et al.
Publicado: (2020)

Liquid Biopsy-based Precision Therapy in Patients with Advanced Solid Tumors: A Real-world Experience from a Community-based Oncology Practice
por: Choucair, Khalil, et al.
Publicado: (2022)

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers
por: Hirshfield, Kim M., et al.
Publicado: (2016)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer
por: Ankeny, J S, et al.
Publicado: (2016)

Enhancing Next‐Generation Sequencing‐Guided Cancer Care Through Cognitive Computing
por: Patel, Nirali M., et al.
Publicado: (2017)

Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases
por: Huang, Richard S P, et al.
Publicado: (2022)

Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary
por: Wang, Xin, et al.
Publicado: (2023)

Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations
por: Koopman, Bart, et al.
Publicado: (2020)

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
por: Liu, Fangcen, et al.
Publicado: (2023)

Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary
por: Fusco, Michael J, et al.
Publicado: (2022)

Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma
por: Yu, Pengfei, et al.
Publicado: (2021)

Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic
por: Napolitano, Stefania, et al.
Publicado: (2022)

Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer
por: Guo, Yun, et al.
Publicado: (2020)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience
por: Pauli, Chantal, et al.
Publicado: (2021)

Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer
por: Murugesan, Karthikeyan, et al.
Publicado: (2022)

Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients
por: Summerer, I, et al.
Publicado: (2015)

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
por: Greystoke, A, et al.
Publicado: (2011)

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design
por: Ross, Jeffrey S., et al.
Publicado: (2020)

The Essentials of Multiomics
por: Marshall, John L, et al.
Publicado: (2022)

Homologous Recombination Deficiency: Concepts, Definitions, and Assays
por: Stewart, Mark D, et al.
Publicado: (2022)

Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings
por: Sturgill, Emma G, et al.
Publicado: (2022)

Artificial Intelligence-based Radiomics in the Era of Immuno-oncology
por: Kang, Cyra Y, et al.
Publicado: (2022)

Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation
por: Huang, Richard S P, et al.
Publicado: (2022)

Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network
por: Dias-Santagata, Dora, et al.
Publicado: (2022)

Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board
por: Green, Michelle F, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_54smg0h55b63oh42mqouupqdb5